Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece.
Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):57-62. doi: 10.1016/j.clml.2019.09.620. Epub 2019 Oct 9.
Multiple myeloma (MM) is an incurable plasma-cell dyscrasia with numerous treatment options currently available; however, drug resistance is usually inevitable, so there is a constant need for novel treatment approaches. The Hippo pathway has emerged as an important mediator of oncogenesis in solid tumors. More recently, its key role in regulating apoptosis and mediating resistance in MM and other hematologic malignancies has been demonstrated in preclinical studies, which provides a strong basis for further clinical investigation. The Hippo pathway is also implicated in the pathogenesis of MM-induced bone disease, as it regulates both osteoblast and osteoclast function. We provide an overview of the available data regarding the role of the Hippo signaling components in the pathophysiology of MM. A better understanding of the underlying interactions at the molecular and cellular levels will lead to novel and promising treatment approaches.
多发性骨髓瘤（MM）是一种不可治愈的浆细胞恶性肿瘤，目前有多种治疗选择；然而，耐药性通常是不可避免的，因此需要不断探索新的治疗方法。Hippo 通路已成为实体瘤中肿瘤发生的重要介质。最近，在临床前研究中已经证明了其在调节多发性骨髓瘤和其他血液恶性肿瘤中的细胞凋亡和介导耐药性方面的关键作用，这为进一步的临床研究提供了坚实的基础。Hippo 通路也与 MM 诱导的骨疾病的发病机制有关，因为它调节成骨细胞和破骨细胞的功能。我们提供了关于 Hippo 信号成分在 MM 病理生理学中的作用的现有数据概述。更好地理解分子和细胞水平上的潜在相互作用将导致新的有前途的治疗方法。
